The impact of GVHD on outcomes after adult single cord blood transplantation in European and Japanese populations.

Adult Cord Blood Stem Cell Transplantation / adverse effects Graft vs Host Disease / etiology Hematopoietic Stem Cell Transplantation Humans Japan Leukemia, Myeloid, Acute Transplantation Conditioning

Journal

Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459

Informations de publication

Date de publication:
01 2022
Historique:
received: 10 07 2021
accepted: 21 09 2021
revised: 09 09 2021
pubmed: 13 10 2021
medline: 22 4 2022
entrez: 12 10 2021
Statut: ppublish

Résumé

The impact of GVHD and graft-versus-leukemia effect in unrelated cord blood transplantation (UCBT) is controversial. In the Eurocord/ALWP EBMT and JSTCT/JDCHCT collaborative study, we evaluated the impact of GVHD on UCBT outcomes in Japanese and European registries. A total of 3,690 adult patients with acute leukemia who received their first single UCBT were included. A multivariate analysis of overall survival (OS) revealed a positive impact of grade II acute GVHD compared with grade 0-I GVHD, in the Japanese cohort (hazard ratio (HR), 0.81; P = 0.001), and an adverse impact in the European cohort (HR, 1.37; P = 0.007). A negative impact of grade III-IV acute GVHD on OS was observed regardless of registries. In the analysis of relapse, a positive impact of grade II acutes GVHD compared with grade 0-I GVHD was observed only in the Japanese cohort, regardless of disease risk. The positive impact of limited chronic GVHD on OS was observed only in the Japanese cohort. In conclusion, a positive impact of mild GVHD after a single UCBT was observed only in the Japanese cohort. This could explain the ethnic difference in UCBT outcomes and might contribute to the preference usage of UCBT in Japan.

Identifiants

DOI: 10.1038/s41409-021-01479-4 PMID: 34635798
pubmed: 34635798
doi: 10.1038/s41409-021-01479-4
pii: 10.1038/s41409-021-01479-4
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

57-64

Informations de copyright

© 2021. The Author(s), under exclusive licence to Springer Nature Limited.

Références

Rocha V. Umbilical cord blood cells from unrelated donor as an alternative source of hematopoietic stem cells for transplantation in children and adults. Semin Hematol. 2016;53:237–45.
pubmed: 27788761 doi: 10.1053/j.seminhematol.2016.08.002
Gratwohl A, Pasquini MC, Aljurf M, Atsuta Y, Baldomero H, Foeken L, et al. One million haemopoietic stem-cell transplants: a retrospective observational study. Lancet Haematol. 2015;2:e91–100.
pubmed: 26687803 doi: 10.1016/S2352-3026(15)00028-9
Cohen YC, Scaradavou A, Stevens CE, Rubinstein P, Gluckman E, Rocha V, et al. Factors affecting mortality following myeloablative cord blood transplantation in adults: A pooled analysis of three international registries. Bone Marrow Transpl. 2011;46:70–6.
doi: 10.1038/bmt.2010.83
Ballen KK, Gluckman E, Broxmeyer HE. Umbilical cord blood transplantation: The first 25 years and beyond. Blood. 2013;122:491–8.
pubmed: 23673863 pmcid: 3952633 doi: 10.1182/blood-2013-02-453175
Rocha V, Gluckman E. Improving outcomes of cord blood transplantation: HLA matching, cell dose and other graft- and transplantation-related factors. Br J Haematol. 2009;147:262–74.
pubmed: 19796275 doi: 10.1111/j.1365-2141.2009.07883.x
Barker JN, Kurtzberg J, Ballen K, Boo M, Brunstein C, Cutler C, et al. Optimal Practices in Unrelated Donor Cord Blood Transplantation for Hematologic Malignancies. Biol Blood Marrow Transpl. 2017;23:882–96.
doi: 10.1016/j.bbmt.2017.03.006
Eapen M, Rocha V, Sanz G, Scaradavou A, Zhang MJ, Arcese W, et al. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol. 2010;11:653–60.
pubmed: 20558104 pmcid: 3163510 doi: 10.1016/S1470-2045(10)70127-3
Eapen M, Klein JP, Sanz GF, Spellman S, Ruggeri A, Anasetti C, et al. Effect of donor-recipient HLA matching at HLA A, B, C, and DRB1 on outcomes after umbilical-cord blood transplantation for leukaemia and myelodysplastic syndrome: a retrospective analysis. Lancet Oncol. 2011;12:1214–21.
pubmed: 21982422 pmcid: 3245836 doi: 10.1016/S1470-2045(11)70260-1
Eapen M, Klein JP, Ruggeri A, Spellman S, Lee SJ, Anasetti C, et al. Impact of allele-level HLA matching on outcomes after myeloablative single unit umbilical cord blood transplantation for hematologic malignancy. Blood. 2014;123:133–40.
pubmed: 24141369 pmcid: 3879902 doi: 10.1182/blood-2013-05-506253
Barker JN, Scaradavou A, Stevens CE. Combined effect of total nucleated cell dose and HLA match on transplantation outcome in 1061 cord blood recipients with hematologic malignancies. Blood. 2010;115:1843–9.
pubmed: 20029048 pmcid: 5003507 doi: 10.1182/blood-2009-07-231068
Verneris MR, Brunstein CG, Barker J, MacMillan ML, DeFor T, McKenna DH, et al. Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units. Blood. 2009;114:4293–9.
pubmed: 19706886 pmcid: 2774557 doi: 10.1182/blood-2009-05-220525
Milano F, Gooley T, Wood B, Woolfrey A, Flowers ME, Doney K, et al. Cord-blood transplantation in patients with minimal residual disease. N Engl J Med. 2016;375:944–53.
pubmed: 27602666 pmcid: 5513721 doi: 10.1056/NEJMoa1602074
Milano F, Gutman JA, Deeg HJ, Nemecek ER, Baumgart J, Thur L, et al. Treosulfan-based conditioning is feasible and effective for cord blood recipients: A phase 2 multicenter study. Blood Adv. 2020;4:3302–10.
pubmed: 32706891 pmcid: 7391133 doi: 10.1182/bloodadvances.2020002222
Kanda J, Nakasone H, Atsuta Y, Toubai T, Yokoyama H, Fukuda T, et al. Risk factors and organ involvement of chronic GVHD in Japan. Bone Marrow Transpl. 2014;49:228–35.
doi: 10.1038/bmt.2013.151
Sharma P, Purev E, Haverkos B, Pollyea DA, Cherry E, Kamdar M, et al. Adult cord blood transplant results in comparable overall survival and improved GRFS vs matched related transplant. Blood Adv. 2020;4:2227–35.
pubmed: 32442301 pmcid: 7252552 doi: 10.1182/bloodadvances.2020001554
Atsuta Y, Kanda J, Takanashi M, Morishima Y, Taniguchi S, Takahashi S, et al. Different effects of HLA disparity on transplant outcomes after single-unit cord blood transplantation between pediatric and adult patients with leukemia. Haematologica. 2013;98:814–22.
pubmed: 23349300 pmcid: 3640130 doi: 10.3324/haematol.2012.076042
Kai S, Wake A, Okada M, Kurata M, Atsuta Y, Ishikawa J, et al. Double-unit cord blood transplantation after myeloablative conditioning for patients with hematologic malignancies: a multicenter phase II study in Japan. Biol Blood Marrow Transpl. 2013;19:812–9.
doi: 10.1016/j.bbmt.2013.02.011
Kanda J, Hayashi H, Ruggeri A, Kimura F, Volt F, Takahashi S, et al. Prognostic factors for adult single cord blood transplantation among European and Japanese populations: the Eurocord/ALWP-EBMT and JSHCT/JDCHCT collaborative study. Leukemia. 2020;34:128–37.
pubmed: 31409921 doi: 10.1038/s41375-019-0534-5
Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transpl. 1995;15:825–8.
Sullivan KM, Agura E, Anasetti C, Appelbaum F, Badger C, Bearman S, et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol. 1991;28:250–9.
pubmed: 1887253
Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M, et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transpl. 2009;15:367–9.
doi: 10.1016/j.bbmt.2008.12.497
Armand P, Kim HT, Logan BR, Wang Z, Alyea EP, Kalaycio ME, et al. Validation and refinement of the disease risk index for allogeneic stem cell transplantation. Blood. 2014;123:3664–71.
pubmed: 24744269 pmcid: 4047501 doi: 10.1182/blood-2014-01-552984
Shouval R, Ruggeri A, Labopin M, Mohty M, Sanz G, Michel G, et al. An integrative scoring system for survival prediction following umbilical cord blood transplantation in acute leukemia. Clin Cancer Res. 2017;23:6478–86.
pubmed: 28754820 doi: 10.1158/1078-0432.CCR-17-0489
Hough R, Danby R, Russell N, Marks D, Veys P, Shaw B, et al. Recommendations for a standard UK approach to incorporating umbilical cord blood into clinical transplantation practice: an update on cord blood unit selection, donor selection algorithms and conditioning protocols. Br J Haematol. 2016;172:360–70.
pubmed: 26577457 doi: 10.1111/bjh.13802
Ballen KK, Logan BR, Laughlin MJ, He W, Ambruso DR, Armitage SE, et al. Effect of cord blood processing on transplantation outcomes after single myeloablative umbilical cord blood transplantation. Biol Blood Marrow Transpl. 2015;21:688–95.
doi: 10.1016/j.bbmt.2014.12.017
Kanda J, Morishima Y, Terakura S, Wake A, Uchida N, Takahashi S, et al. Impact of graft-versus-host disease on outcomes after unrelated cord blood transplantation. Leukemia. 2017;31:663–8.
pubmed: 27748373 doi: 10.1038/leu.2016.288
Baron F, Ruggeri A, Beohou E, Labopin M, Mohty M, Sanz J, et al. Occurrence of graft-versus-host disease increases mortality after umbilical cord blood transplantation for acute myeloid leukaemia: A report from Eurocord and the ALWP of the EBMT. J Intern Med. 2018;283:178–89.
pubmed: 28977716 doi: 10.1111/joim.12696
Chen YB, Wang T, Hemmer MT, Brady C, Couriel DR, Alousi A, et al. GvHD after umbilical cord blood transplantation for acute leukemia: An analysis of risk factors and effect on outcomes. Bone Marrow Transpl. 2017;52:400–8.
doi: 10.1038/bmt.2016.265
Kanda J, Umeda K, Kato K, Murata M, Sugita J, Adachi S, et al. Effect of graft-versus-host disease on outcomes after pediatric single cord blood transplantation. Bone Marrow Transpl. 2020;55:1430–7.
doi: 10.1038/s41409-020-0853-1
Murata M, Nakasone H, Kanda J, Nakane T, Furukawa T, Fukuda T, et al. Clinical factors predicting the response of acute graft-versus-host disease to corticosteroid therapy: an analysis from the GVHD working group of the japan society for hematopoietic cell transplantation. Biol Blood Marrow Transpl. 2013;19:1183–9.
doi: 10.1016/j.bbmt.2013.05.003
Oh H, Loberiza FR Jr., Zhang MJ, Ringden O, Akiyama H, Asai T, et al. Comparison of graft-versus-host-disease and survival after HLA-identical sibling bone marrow transplantation in ethnic populations. Blood. 2005;105:1408–16.
pubmed: 15486071 doi: 10.1182/blood-2004-06-2385
Kanda J, Brazauskas R, Hu ZH, Kuwatsuka Y, Nagafuji K, Kanamori H, et al. Graft-versus-host disease after HLA-matched sibling bone marrow or peripheral blood stem cell transplantation: Comparison of north American caucasian and Japanese populations. Biol Blood Marrow Transpl. 2016;22:744–51.
doi: 10.1016/j.bbmt.2015.12.027
Morishima Y, Kawase T, Malkki M, Morishima S, Spellman S, Kashiwase K, et al. Significance of ethnicity in the risk of acute graft-versus-host disease and leukemia relapse after unrelated donor hematopoietic stem cell transplantation. Biol Blood Marrow Transpl. 2013;19:1197–203.
doi: 10.1016/j.bbmt.2013.05.020
Morishima S, Ogawa S, Matsubara A, Kawase T, Nannya Y, Kashiwase K, et al. Impact of highly conserved HLA haplotype on acute graft-versus-host disease. Blood. 2010;115:4664–70.
pubmed: 20335219 doi: 10.1182/blood-2009-10-251157
Kanda J, Kawase T, Tanaka H, Kojima H, Morishima Y, Uchida N, et al. Effects of haplotype matching on outcomes after adult single-cord blood transplantation. Biol Blood Marrow Transpl. 2020;26:509–18.
doi: 10.1016/j.bbmt.2019.09.035
de Koning C, Admiraal R, Nierkens S, Boelens JJ. Immune reconstitution and outcomes after conditioning with anti-thymocyte-globulin in unrelated cord blood transplantation; the good, the bad, and the ugly. Stem Cell Investig. 2017;4:38.
pubmed: 28607912 pmcid: 5460145 doi: 10.21037/sci.2017.05.02
Pascal L, Tucunduva L, Ruggeri A, Blaise D, Ceballos P, Chevallier P, et al. Impact of ATG-containing reduced-intensity conditioning after single- or double-unit allogeneic cord blood transplantation. Blood. 2015;126:1027–32.
pubmed: 26160301 doi: 10.1182/blood-2014-09-599241
Admiraal R, Lindemans CA, van Kesteren C, Bierings MB, Versluijs AB, Nierkens S, et al. Excellent T-cell reconstitution and survival depend on low ATG exposure after pediatric cord blood transplantation. Blood. 2016;128:2734–41.
pubmed: 27702800 doi: 10.1182/blood-2016-06-721936
Brunstein CG, Weisdorf DJ, DeFor T, Barker JN, Tolar J, van Burik JA, et al. Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation. Blood. 2006;108:2874–80.
pubmed: 16804113 pmcid: 1895580 doi: 10.1182/blood-2006-03-011791
de Koning C, Prockop S, van Roessel I, Kernan N, Klein E, Langenhorst J, et al. CD4 + T-cell reconstitution predicts survival outcomes after acute graft-versus-host-disease: A dual-center validation. Blood. 2021;137:848–55.
pubmed: 33150379 pmcid: 7986048 doi: 10.1182/blood.2020007905
Lazaryan A, Weisdorf DJ, DeFor T, Brunstein CG, MacMillan ML, Bejanyan N, et al. Risk factors for acute and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation with umbilical cord blood and matched sibling donors. Biol Blood Marrow Transpl. 2016;22:134–40.
doi: 10.1016/j.bbmt.2015.09.008

Auteurs

Junya Kanda (J)

Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan. jkanda16@kuhp.kyoto-u.ac.jp.
ORCID: 0000-0002-6704-3633

Hiromi Hayashi (H)

Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Eurocord, Hospital Saint Louis, AP-HP, IUH University Paris VII, Paris, France.
Monacord, Centre Scientifique de Monaco, Monaco, Monaco.

Annalisa Ruggeri (A)

Eurocord, Hospital Saint Louis, AP-HP, IUH University Paris VII, Paris, France.
Monacord, Centre Scientifique de Monaco, Monaco, Monaco.
Haematology and Bone Marrow Transplant Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
ORCID: 0000-0002-7261-2765

Fumihiko Kimura (F)

Division of Hematology, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan.
ORCID: 0000-0001-6223-9904

Fernanda Volt (F)

Eurocord, Hospital Saint Louis, AP-HP, IUH University Paris VII, Paris, France.
Monacord, Centre Scientifique de Monaco, Monaco, Monaco.

Satoshi Takahashi (S)

Division of Molecular Therapy, The Advanced Clinical Research Center The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

Shinichi Kako (S)

Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.
ORCID: 0000-0002-2635-3395

Karina Tozatto-Maio (K)

Eurocord, Hospital Saint Louis, AP-HP, IUH University Paris VII, Paris, France.
Monacord, Centre Scientifique de Monaco, Monaco, Monaco.
Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, Brazil.

Masamitsu Yanada (M)

Department of Hematology and Cell Therapy, Aichi Cancer Center, Nagoya, Japan.
ORCID: 0000-0003-1602-9775

Guillermo Sanz (G)

Hematology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain & CIBERONC, Madrid, Spain.
ORCID: 0000-0002-2767-8191

Naoyuki Uchida (N)

Department of Hematology, Toranomon Hospital, Tokyo, Japan.
ORCID: 0000-0001-5952-5926

Emanuele Angelucci (E)

Hematology and Transplant Center, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.

Seiko Kato (S)

Department of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

Mohamad Mohty (M)

Service d'Hématologie Clinique et de Thérapie cellulaire, APHP, Hôpital Saint Antoine, Paris, France.
Sorbonne University, Paris, France.
ORCID: 0000-0002-7264-808X

Edouard Forcade (E)

CHU Bordeaux, service d'hematologie et therapie cellulaire, Bordeaux, France.
ORCID: 0000-0002-8873-2868

Masatsugu Tanaka (M)

Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan.

Jorge Sierra (J)

Hospital Santa Creu i Sant Pau Hematology Department, Barcelona, Catalunya, Spain.
ORCID: 0000-0002-7966-0356

Takanori Ohta (T)

Department of Internal Medicine, Kitakyushu Municipal Medical Center, Kitakyushu, Japan.

Riccardo Saccardi (R)

Azienda Ospedaliera Universitaria Careggi Cell Therapy and Transfusion Medicine Unit, Firenze, Italy.
ORCID: 0000-0002-5763-5467

Takahiro Fukuda (T)

Hematopoietic Stem Cell Transplantation Division, National Cancer Center Hospital, Tokyo, Japan.

Tatsuo Ichinohe (T)

Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
ORCID: 0000-0002-0393-4066

Takafumi Kimura (T)

Preparation Department, Japanese Red Cross Kinki Block Blood Center, Ibaraki, Japan.

Vanderson Rocha (V)

Eurocord, Hospital Saint Louis, AP-HP, IUH University Paris VII, Paris, France.
Monacord, Centre Scientifique de Monaco, Monaco, Monaco.

Shinichiro Okamoto (S)

Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.

Arnon Nagler (A)

Division of Hematology and Bone Marrow Transplantation, The Chaim Sheba Medical Center, Tel-Hashomer, Ramat-Gan, Israel.
EBMT Data Office, Hôpital Saint Antoine, Paris, France.
ORCID: 0000-0002-0763-1265

Yoshiko Atsuta (Y)

Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan.
ORCID: 0000-0003-4404-2870

Eliane Gluckman (E)

Eurocord, Hospital Saint Louis, AP-HP, IUH University Paris VII, Paris, France.
Monacord, Centre Scientifique de Monaco, Monaco, Monaco.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › The impact of GVHD on outcomes after adult...
questionsmedicales.fr › Procédures de chirurgie opératoire › Transplantation › Transplantation cellulaire › Transplantation de cellules souches › Transplantation de cellules souches de sang du cordon › The impact of GVHD on outcomes after adult...
questionsmedicales.fr › Maladies du système immunitaire › Maladie du greffon contre l'hôte › The impact of GVHD on outcomes after adult...
questionsmedicales.fr › Procédures de chirurgie opératoire › Transplantation › Transplantation cellulaire › Transplantation de cellules souches › Transplantation de cellules souches hématopoïétiques › The impact of GVHD on outcomes after adult...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › The impact of GVHD on outcomes after adult...
questionsmedicales.fr › Régions géographiques › Iles › Japon › The impact of GVHD on outcomes after adult...
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Leucémies › Leucémie myéloïde › Leucémie aigüe myéloïde › The impact of GVHD on outcomes after adult...
questionsmedicales.fr › Techniques d'investigation › Techniques immunologiques › Immunosuppression thérapeutique › Conditionnement pour greffe › The impact of GVHD on outcomes after adult...